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Abstract. The ability of tumoral cells to invade sur- development of metastasis is a multistep process that
requires coordinated activation of proliferation, motil-rounding tissues is a prerequisite for metastasis. This is
ity, changes in normal cell-to-cell and cell-to-substratethe most life-threatening event of tumor progression,
contacts, degradation of extracellular matrix, inhibitionand so research is intensely focused on elucidating the
mechanisms responsible for invasion and metastasis. of apoptosis, and adaptation to an inappropriate tissue
The Ras superfamily of GTPases comprises several sub- environment. Several members of the Ras superfamily
of proteins have been implicated in these processes. Thefamilies of small GTP-binding proteins whose functions
include the control of proliferation, differentiation, and present review summarizes the current knowledge in
apoptosis, as well as cytoskeleton organization. The this field.
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Introduction
Metastasis is the most common and serious, life-threat-
ening complication of cancer. At the time of cancer
diagnosis, almost 50% of the patients have already
developed metastasis [1]. The discovery of oncogenes
(mutated forms of normal cellular genes involved in
growth control) identified the genetic basis of cancer.
Many intracellular pathways that control cell growth
are now known, and alterations in these normal routes
are key events in the generation of tumors. In contrast,
the molecular mechanisms responsible for the acquisi-
tion of metastatic ability are poorly understood.
The most important oncogene in humans is ras, which
has been implicated in up to 30% of all cancers. The ras
genes were first found as the transforming sequence in
murine acute transforming retrovirus and in experi-
ments aimed to isolate transforming genes derived from
human tumoral DNA [2]. The Ras superfamily of
proteins is a large group of small molecular-mass
proteins belonging to the larger group of GTP-binding
proteins or G proteins [3, 4]. All these proteins share the
ability to bind guanine nucleotides and are able to
hydrolyze GTP. They function as molecular switches,
and can be found in two different states, GDP or GTP
bound. These small GTPases have a higher affinity for
GDP than for GTP, so in resting conditions they bind
GDP. After delivery of the appropriate signal, specific
exchange factors interact with them promoting the re-
lease of GDP and the binding of GTP. This presumably
induces a conformational change in the small GTPases
that enables them to interact with their targets. When
the GTP is hydrolyzed by the intrinsic GTPase activity,
the cycle is completed and the small GTPase returns to
its resting, GDP-bound conformation [4]. The endoge-
nous GTPase activity is enhanced by interaction with
specific catalytic factors termed GTPase activating
proteins (GAPs).
The distinct members of the Ras superfamily are in-
volved in a wide diversity of cellular functions, the Ras
and Rho groups being of special interest because they
are implicated in the development and progression of* Corresponding author.
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malignancies. The Ras proteins are key components of
the signal transduction pathways triggered by a large
number of different extracellular signals, including mi-
togens [4]. Ras proteins are targeted to the plasma
membrane by specific posttransductional modifications
in their carboxyl-terminal region [5] and this cellular
localization is critical for their function [6]. The mecha-
nism of Ras protein activation by extracellular signals
has been studied in detail for growth factors such as
epidermal growth factor (EGF) [7]. After activation of
the appropriate membrane receptor by its agonist, Sos,
an exchange factor for Ras proteins, is recruited to the
receptor tyrosine kinase with the aid of adapter
molecules such as Grb2 [8]. The translocation of Sos
from cytoplasm to the receptor at the plasma mem-
brane brings it close to Ras proteins, facilitating their
interaction and consequent activation [9, 10]. In their
GTP-bound conformation, Ras proteins can interact
with several molecules resulting in their activation.
Among Ras targets, the serine/threonine kinase Raf
[11–13], Ral-GDS [14, 15], and the phosphatidyl inosi-
tol 3-kinase (PI3K) [16] are the best characterized. Raf
is the first step in a cascade of cytosolic kinases, known
as the mitogen-activated protein kinase (MAPK) cas-
cade, which leads to the phosphorylation of several
intracellular substrates including transcription factors
[17]. PI3K can be activated by Ras proteins or by direct
interaction with receptor tyrosine kinases. Upon activa-
tion, it phosphorylates phosphatidyl inositol at position
3 of the inositol ring. The resulting lipids are second
messengers that mediate the activation of various
molecules including the small GTP-binding protein
Rac, certain Ser/Thr kinases of the protein kinase C
(PKC) family and the Ser/Thr kinase Akt/PKB [18].
Ral-GDS regulates another group of small GTPases of
this superfamily, Ral, which may directly control phos-
pholipase D [18] with the subsequent generation of
important lipid-derived second messengers such as
phosphatidic acid (PA) and diacylglycerol (DAG) [19].
The Rho family of proteins includes several members:
Rho A, Rho B, Rho C, Rho D, Rho E, Rho G, TC10,
Rac1A, Rac1B, Rac2, CDC42Hs, and G25K [20].
These proteins play a critical role in the regulation of
the cytoskeleton [20] as well as in signal transduction of
different stimuli [21]. Interestingly, some of the Rho
proteins are able to induce transformation of cells in
culture and are tumorigenic in vivo [22]. The exact
mechanism of Rho activation is unclear but at least in
some instances they localize downstream of Ras [23–
25]. Rho proteins are involved in the activation of c-Jun
N-terminal kinase (JNK) and the transcription factors
NF-kB [26, 27] and serum response factor [28, 29].
However, elucidation of the direct targets for these
proteins is only just beginning.
The Ras superfamily of proteins is involved not only in
induction of the transformed phenotype, but also in the
acquisition of metastatic behavior which can be consid-
ered the last step in tumoral progression. The possible
role of several members of the Ras superfamily in the
generation of metastasis is discussed here, with a focus
on the molecular mechanisms by which they contribute
to this process.
Role of the Ras superfamily in metastasis
Steps in the metastatic process
The generation of metastasis is a complex process,
which involves several subsequent steps, as shown sche-
matically in figure 1, that allow a cell to escape from the
primary tumor, travel through the blood or lymph
vessels, and establish a secondary tumor in a distant
location [30]. Invasion is the first step toward metastasis
and it requires loss of normal cell-to-cell interactions to
allow individual cells to emigrate from the tumoral
mass. Special organizations of the extracellular matrix
(ECM), e.g., basement membranes, are barriers that
tumors have to destroy to gain access to adjacent or
distant organs. In most cases, this last event defines the
malignancy of a tumor because it is usually the cause of
death in cancer patients [31]. Invasive tumoral cells can
degrade the ECM by altering the normal equilibrium of
the ECM-degradative enzymes (see Johansson et al. and
Andreasen et al. in this multi-author review). Tumoral
cells find their way to distant organs following the
blood or lymphatic circulation. In both cases, the first
step consists of permeation of the vessels. This process
is facilitated by the newly formed blood vessels in the
tumor, a phenomenon called angiogenesis. Survival in
the blood stream is the next challenge that tumoral cells
have to face before reaching a new location. The estab-
lishment of a secondary tumor requires not only the
ability of the cells to invade, but also to survive and
proliferate in a distant location, usually a different
organ in which they have to adapt to a new tissue
environment.
Involvement of Ras proteins in metastasis
Ras proteins were first described as the products of the
transforming oncogene in a rodent acute transforming
retrovirus. Soon thereafter, ras oncogenes were iden-
tified as the transforming sequences from human tumor
DNA [reviewed in ref. 2]. Many pioneer studies de-
scribed how ras-transformed cells show some character-
istics of the metastatic phenotype such as invasion of
artificial basal membranes, and the ability to colonize
the lung of mice following intravenous injection, an
approach usually referred to as the experimental metas-
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tasis assay [32, 33]. However, this is a controversial
issue, since not all ras-transformed cell lines show this
behavior [32–37]. Moreover, when more physiological
and stringent models, such as the spontaneous metasta-
sis assay, were used to test their metastatic capability, in
many cases ras failed to confer the full metastatic phe-
notype [34–39]. In the spontaneous metastasis assay,
oncogene-transformed cells are injected subcutaneously
in recipient animals. When the primary tumor reaches a
fixed volume, it is resected and the animal is monitored
for the development of metastasis. Thus this assay re-
sembles more accurately natural tumor progression.
One possible explanation for the conflicting results re-
garding the ability of Ras proteins to confer metastatic
ability is the fact that different cell types were used in
most studies. This may imply that ras itself is not
sufficient and needs to cooperate with other pre-existing
factors which are present in only some of the cell types
used [33]. In agreement with this idea, it has been shown
that the expression of oncogenic ras in combination
with c-myc in rat and hamster lung fibroblasts confers
on cells a metastatic potential, while expression of ras
or myc alone fails to confer the metastatic phenotype
[39].
Alternatively, ras could be responsible for the full
metastatic phenotype indirectly, by promoting the ac-
quisition of cumulative alterations in cellular pathways
that can not only transform a cell, but also confer
metastatic capability. Supporting this hypothesis, trans-
formation of nonmetastatic rat mammary [40] and pro-
static [41] cancer cells with oncogenic ras does not
always correlate with the acquisition of metastatic abil-
ity but it does correlate with ras-induced chromosomal
abnormalities. Thus, ras affected metastatic ability indi-
rectly, presumably by promoting genetic instability. The
hypothesis that ras induces some cellular change that is
ultimately responsible for the induction of metastasis is
further supported by studies in which ras-transformed
cells that had acquired the metastatic phenotype but
lost ras expression retained the metastatic phenotype
[42].
Independent of the mechanism involved, the participa-
tion of Ras proteins in the progression of human can-
cers has been extensively studied. Analysis of clinical
Figure 1. Steps in tumoral progression towards metastasis. The basic steps that cells have to complete to give rise to metastasis are
boxed. Primary tumors usually contain a heterogeneous mixture of cells, and mutant clones with specific characteristics arise during
tumorigenesis. The selection in tumors promotes the overgrowth of only some of the variant clones that have developed a selective
advantage. The alterations that cells have to acquire to successfully complete each step are indicated on the right.
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samples has revealed a statistical association between
increased Ras function (overexpression and/or activat-
ing mutations) and metastasis in a wide array of human
malignancies such as carcinomas of the colon [43, 44],
cervix [45], breast [46, 47] and stomach [48]. All these
studies suggest that Ras oncoproteins play an important
role not only in the generation but also in the progres-
sion of human cancers.
Involvement of Rho proteins in metastasis
In addition to ras, the rho family of genes are also able
to promote cellular transformation, although with much
less potency [22, 49]. In contrast to ras, no mutation in
the rho genes has been found in association with human
cancer, although overexpression of the rho C gene is
associated with the progression of human pancreatic
carcinoma [50]. Recent studies suggest that Rho proteins
mediate some of the effects of ras oncogenes in transfor-
mation [23]. Consistently, dominant negative forms of
these proteins block ras-induced transformation [24],
whereas active forms cooperate with other Ras effectors
such as the Ser/Thr kinase Raf to induce transformation
[25, 51]. Hence, at least part of the Ras transformation
ability may be mediated by Rho proteins.
Probably because Rho proteins are not very potent
oncogenes, their possible role in the induction of metas-
tasis has received little attention. An elegant study aimed
to search for genes involved in metastatic progression
led to the discovery of Tiam-1 [52]. The sequence of the
Tiam-1 protein suggested that it might function as an
exchange factor for Rho proteins. Tiam-1 was then
demonstrated to be an exchange factor for Rac proteins
in vitro, and consistently activated forms of Rac protein
were found to promote invasion in vitro [53, 54]. This
was the first study showing that proteins of the Rho
family may promote metastatic behavior, at least in
vitro. Finally, it has recently been reported that transfor-
mation of mouse fibroblasts with different proteins of
the Rho family as well as with oncogenes that function
as exchange factors for these proteins results in the
acquisition of a metastatic phenotype in vivo, even in
the spontaneous metastasis assay [38]. As mentioned
before, amplification of a gene of the rho family, rho C,
is associated with metastatic progression in human pan-
creatic cancer [50], the first clinical evidence implicating
these proteins in promoting metastasis.
Molecular mechanisms by which Ras proteins affect
metastasis
Effects on the cytoskeleton
The homeostasis of a tissue is maintained by continuous
exchange of signals between the cells and the ECM. This
is necessary for the accurate coordination of cells and
stroma that distinguish a particular tissue. Most of this
information is believed to be transmitted from the sur-
face to the intracellular machinery by changes in the
cytoskeleton. One of the most important features in the
origin of a tumor is escape from this regulation, which
leads to the autonomous proliferation of a clone of cells.
The metastatic behavior can be considered as a further
step in which the tumoral cells ignore not only the
negative signals to proliferation but also to migration
out of the original tissue. Again, the cytoskeleton plays
an important role in motility and invasion, and the Ras
superfamily of GTPases has been implicated in these
processes. In fact, an effect on the cytoskeleton was the
first function attributed to the Rho family of proteins
[20]. The first studies demonstrated that Rho stimulates
the organization of actin stress fibers, Rac induces the
formation of lamellipodia, and Cdc42 is responsible for
the appearance of filopodia [55, 56]. These proteins can
act in a coordinate fashion to provide motility to the
cell, and a cascade of activation has been described from
Cdc42 through Rac to Rho.
Adhesion: cell-cell/cell-ECM. The interaction of cells
with the ECM is mediated by contacts between cellular
surface proteins called integrins and components of the
ECM like laminin or fibronectin. Integrins are adhesion
molecules present as heterodimers that upon activation
by binding to specific extracellular ligands can influence
intracellular signaling pathways. They can modulate not
only motility and other functions associated with the
cytoskeleton, but also proliferation of the cell [57–59].
Integrins cluster in cellular structures called focal com-
plexes whose formation is stimulated by Rho, Rac, and
Cdc42. These complexes constitute a physical and func-
tional connection between the extracellular and intracel-
lular environments, as suggested by the association of
important molecules such as PI3K, focal adhesion ki-
nase (FAK), and members of the MAPK cascade [57,
59]. This mutual influence can be executed from inside to
outside, because the affinity of integrins for their extra-
cellular ligands can be modulated by events coming
from inside the cell [59]. The relationship between inte-
grins and members of the Ras superfamily of GTPases
in driving changes in the cell-ECM interaction has
recently been emphasized for different cell lines like
fibroblasts [60] and lymphocytes [61].
Malignant cells often present imbalances in this delicate
equilibrium, with activation of aberrant pathways lead-
ing to invasion and metastasis. Members of the Rho
family of GTPases can participate in these processes.
The activation of integrin a6b1 by laminin promotes
tyrosine phosphorylation of a GTPase-activating
protein for Rho, resulting in activation of the G protein
and promotion of changes in the cytoskeleton leading to
formation of membrane-protrusive structures called
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invadipodia [62]. In addition, in vitro studies using
mammary epithelial cells in a collagenous matrix have
revealed that Cdc42 and Rac can mediate invasiveness
by activation of PI3K in an integrin-mediated path-
way [55].
Cadherins are calcium-dependent homophylic cell-cell
adhesion molecules whose altered function has been
implicated in the pathogenesis of metastasis. E-cad-
herin is believed to have anti-invasive activity. Ras
superfamily involvement in cadherin-mediated adhe-
sion is controversial. Some reports indicate an in-
hibitory role for Rho [63], Cdc42 and Rac [64] in this
process, while others describe opposing effects [65, 66].
The use of different cell lines could lie behind some of
these discrepancies. They may in addition reflect the
complex dynamics of these processes, because invasion
needs constant remodeling of the cytoskeleton and the
attachment/detachment of cells to the ECM.
Ras proteins can moreover modulate the adhesion of
tumoral cells by increasing the expression of the sur-
face glycoprotein CD44 and increasing the frequency
of splicing variants which are implicated in metastasis
[67]. Finally, Ras, Rac and PI3K have been shown to
mediate the antiadhesion activity of the prometastatic
ligand hepatocyte growth factor/scatter factor (HGF/
SF) [68]. HGF binds to the product of the proto-
oncogene met, a tyrosine kinase receptor that upon
activation promotes the cell dissociation of many ep-
ithelial cells. It has important physiological functions
in embryogenesis, when specific populations of cells
need to migrate and proliferate in locations different
from their original tissue. This behavior resembles the
metastatic phenotype and, in fact, overexpression of
Met has been detected in several human cancers [69,
70].
Migration. The modulation of cytoskeleton organiza-
tion and adhesion to substrates can greatly determine
the motility of cells. It is therefore not surprising that
Rac and Ras have been implicated in the chemotactic
response to platelet-derived growth factor (PDGF)
[71, 72]. This process can be mediated by the enzymes
phospholipase C-g (PLC-g) and PI3K, whereas GAP
has an inhibitory effect, in keeping with the participa-
tion of Ras in migration. Moreover, MAPK, one of
the downstream components of the Ras signaling
pathways, can induce the activating phosphorylation
of the myosin light chain (MLC) kinase (MLCK),
which in turn phosphorylates and activates MLC re-
sulting in enhanced motility [73]. Rho-associated ki-
nase, a proposed effector of Rho, is able to directly
phosphorylate MLC and induce contractility in
smooth muscle cells [74]. In addition, Rho A-overex-
pressing rat hepatoma cells show enhanced phospho-
rylation of MLC, and inhibitors of MLCK reduce
their invasiveness [75].
PTEN, a recently identified tumor suppressor gene
found mutated in many human tumors [76], codes for
a phosphatase that removes the phosphate in position
D3 of the phosphatidyl-inositol 3,4,5-triphosphate (PI
3,4,5-P3) [77]. This lipid is the product of PI3K and
has an important role as a second messenger. Rac-1 is
one of the molecules activated by PI 3,4,5-P3 [78].
Interestingly, overexpression of PTEN blocks migra-
tion [79] while active forms of Rac-1 have been shown
to promote migration [55], suggesting that PTEN may
prevent migration by removing the lipid second mes-
senger PI 3,4,5-P3 that activates Rac-1. Consistently,
PTEN is mutated as a late event during tumorigenesis
[76], implying that inactivation of this gene is required
for some of the late events of tumor progression such
as the generation of metastasis.
Intra/extravasation. The ability of cancer cells to cross
the capillary wall and migrate into/out of lymphatic
and blood vessels is conceptually a very important
property for the metastatic phenotype. However, some
recent data suggest that this might not be a limiting
step in the development of metastasis. When
metastatic ras-transformed fibroblasts and control
fibroblasts were compared, both showed the same
ability to extravasate from the capillary plexus of
chicken embryo chorioallantoic membrane [80]. In ad-
dition, when B16F1 melanoma cells were injected in
the portal vein of mice, 80% were able to survive in
the liver microcirculation and extravasate by day 3. In
this model system, the most stringent step for the de-
velopment of macroscopic metastasis was the survival
and proliferation of cells once they reached the liver
[81].
The study of this phenomenon is hampered by the
difficulty establishing good in vitro models. There are
a few reports that directly implicate members of the
Ras superfamily of GTPases like Rho [75] and Cdc42
[82] in the invasion of cell monolayers (transmigra-
tion). However, an emerging concept in this field is
that adhesion molecules like integrins and cadherins
play important roles, and that endothelial cells are not
passive elements in this process [83].
Effects on gene expression
Induction of proteases. Apart from effects on the cy-
toskeleton, members of the Ras family of GTPases
can modulate the expression of genes involved in some
of the metastatic steps. Among these are several types
of protease whose function is the degradation of ECM
components. These enzymes are physiologically ex-
pressed by macrophages and other cells in the context
of inflammation, wound healing, and other circum-
stances requiring remodeling of tissue. The same or
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more specific proteases can assist invasion of metastatic
cells. These cells can shift the proteolytic balance of the
surrounding tissue by direct production of the
proteases, by inducing their secretion in stromal fibro-
blast, or by reducing protease inhibitors [84].
There is abundant information linking the ras oncogene
with the expression of proteases and tumor invasion.
The 92-kDa type IV collagenase/gelatinase B/matrix
metalloproteinase-9 (MMP-9) is one MMP most fre-
quently associated with Ras [85–91]. Overexpression of
the 72-kDa MMP-2 has also been linked to this onco-
gene in vitro [86] and in human malignancy [45].
Laminin induces the expression of MMP-2 through
phospholipase D (PLD), an enzyme that cleaves phos-
phatidylcholine into PA and choline [92]. In agreement
with this mechanism of activation, the intracellular lib-
eration of PA increases the release of MMP-2 in
metastatic fibrosarcoma cells [93]. Interestingly, acti-
vated forms of Rho [94, 95] and Ras [96–99] proteins
have been proposed to induce the activation of PLD,
raising the possibility that PLD acts as a link between
oncogenic Ras proteins and protease induction. An-
other MMP, matrilysin (MMP-7), was induced by Ras
transfection in colon cancer cells by an AP-1-dependent
pathway [100]. Ras may also mediate the upregulation
of proteases induced by physiological stimuli. The list of
tissue proteases induced by Ras includes urokinase or
tissue-type plasminogen activators, depending on the
cells studied [101, 102], and the cysteine proteases
cathepsin C and L [103, 104]. As mentioned above, Ras
can also alter the proteolytic balance causing a reduc-
tion in the levels of tissue inhibitors of metallo-
proteinases (TIMPs) and cystatins [91, 105, 106].
Induction of other genes. In addition to proteases, many
other metastasis-related genes have been found to be
regulated by Ras proteins. Ras induces the expression
of metastasis-associated isoforms of the adhesion
molecule CD44 [67, 87]. The expression of vascular
endothelial growth factor (VEGF) correlates with the
level of expression of activated Ras proteins in a model
of mouse skin carcinogenesis [107]. VEGF is a potent
angiogenic factor that promotes the growth of new
blood vessels, a step required in the generation of
metastasis [1]. Expression of nm-23, a gene involved in
suppression of the metastatic phenotype, is repressed by
Ras [87, 105]. Interestingly, several studies [108] demon-
strate that adenovirus E1a protein blocks these alter-
ations in gene expression and prevents Ras-induced
metastatic behavior without affecting its tumorogenic
potential [109]. In addition, this viral protein is able to
block the Ras-induced transcriptional activation of sev-
eral ECM proteases that may be important for the
development of metastasis [90, 110]. Little is known
about the coordination of migration and degradative
processes. However, fibronectin was recently shown to
induce the secretion of MMP-9 in ovarian cancer cells
in a FAK- and Ras-dependent pathway [111].
Inhibition of apoptosis. Apoptosis is the process by
which a cell dies in a neat orderly way that does not
alter the structure or function of the tissue in which it is
located [112]. The induction of apoptosis is an impor-
tant mechanism to control cell number and delete un-
wanted cells [113, 114]. The apoptosis program is
believed to be latent in all cells and has to be constantly
suppressed by extracellular survival signals in order to
keep cells alive. The survival signals from the environ-
ment are very diverse, and include growth factors, cy-
tokines, hormones, and contacts between cells and
between the cells and the ECM. Hence each cell type
constantly receives from its normal environment the
required survival signals that prevent the activation of
the endogenous apoptotic program [113, 114]. This sys-
tem is very useful for controlling the number of cells in
a tissue. Since the survival signals are limited, they can
support only a limited, fixed number of cells. This
system also ensures that the cells are in the appropriate
location. Misplaced cells fail to receive the appropriate
survival signals and die. The usefulness of this system is
especially apparent during the development of the cen-
tral nervous system where an excess neurons are pro-
duced, but only those that are able to make the correct
contacts receive the required survival factors and sur-
vive. The remainder are eliminated by apoptosis with-
out compromising the integrity of the tissue. Thus this
apoptosis by default regulates both the total number of
neurons and their localization.
As expected, alteration of the normal apoptotic path-
ways has a profound impact in tumorogenesis at many
levels [115, 116]. Failure to undergo apoptosis results in
the accumulation of cells leading to the formation of a
tumor. Bcl-2 is a critical protein in the apoptotic ma-
chinery that promotes survival. Overexpression of Bcl-2
due to certain chromosomal translocations results in the
generation of human lymphomas and leukemias [117–
119]. But apoptosis has been implicated not only in the
initiation of tumors but also in their progression. Tu-
moral cells usually present genetic instability and the
accumulation of mutations is critical for the generation
of new clonal cell populations with more aggressive
behavior. Under normal conditions, seriously damaged
cells undergo apoptosis. Disruption of this process leads
to the accumulation of cells that bear unrepaired
mutations.
The alteration of the normal apoptotic response also
plays an important role in the development of metasta-
sis. As discussed above, cells are tightly attached to one
another and to the ECM. Disruption of these cell-cell
contacts and alterations in adhesion to the ECM are
first steps toward metastasis. Importantly, these interac-
tions are strong survival signals and most adherent cells
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require these contacts to survive. The term anoikis
refers to the induction of apoptosis by detachment of
cells [120–122]. Hence, to metastasize, cells have to
avoid the induction of apoptosis due to the lack of
normal cell-cell and cell-ECM contacts. Ras onco-
proteins are able to prevent anoikis in epithelial cells
upon detachment [123] by activating a potent survival
signal through the activation of PI3K [123]. Thus, ac-
tivated Ras proteins contribute to the generation of
metastasis by inhibiting apoptosis. Moreover, cell
transformation usually increases the sensitivity of cells
to apoptotic stimuli, which could be an evolutionarily
developed mechanism to prevent unwanted cell divi-
sion [124]. Transformation of cells with the myc onco-
gene, which is present in a large number of human
malignancies, renders cells extremely sensitive to
apoptosis [125, 126]. Transfection of active Ras
proteins in myc-transformed cells completely abolishes
the Myc-mediated sensitivity to apoptosis [127]. This
cooperation between oncogenes may be crucial for
the completion of the different steps during tumor
progression, and it may be more than a mere coinci-
dence that, at least in some systems, generation of
metastasis requires both ras and myc oncogenes (see
above).
A number of other steps during tumor progression
are limited by the induction of apoptosis. A charac-
teristic of most solid tumors is that the internal part
of the tumor is usually hypoxic, a condition that may
induce apoptosis. Development of metastasis in dis-
tant tissues and, usually, organs different from the
original one, imply growth of tumoral cells in an un-
familiar environment that probably lack the required
specific survival signals. No literature is available on
the effect of Ras proteins in these situations; however,
the fact that Ras proteins activate a potent antiapop-
totic pathway [123, 127] suggests that ras oncogenes
may help to prevent apoptosis in these situations.
Supporting this idea, ras oncogenes have been shown
to render cells resistant to the killing effect of many
chemotherapeutic drugs [128]. Finally, members of the
Rho family of GTPases have been demonstrated to
induce apoptosis under conditions of serum depriva-
tion [129–131]. Although the physiological role of this
effect must be further characterized, knowledge of the
signal transduction pathways altered by either Ras or
Rho proteins may be essential for understanding the
regulation of proliferating versus apoptotic signals
[132], which may in turn bring some light to bear on
understanding the onset of metastasis. Most anti-
cancer drugs kill cells by activating the endogenous
apoptotic program, and development of resistance to
these therapies seems to be due to disruption of the
normal apoptotic program or activation of antiapop-
totic pathways [133].
Conclusions
Study of the mechanisms leading to the acquisition of a
metastatic phenotype in tumoral cells is one of the
major topics in cancer research. It constitutes a prereq-
uisite for the development of new therapeutic agents
aimed to inhibit the establishment and growth of metas-
tases once a primary cancer has been diagnosed. The
data available so far have only started to reveal the
complexity of this multistep process. The Ras superfam-
ily of GTPases has been implicated in virtually all the
events related to cancer metastasis (a schematic repre-
sentation of their involvement is depicted in figure 2).
This is mostly due to the involvement of these proteins
in the control of both proliferation and motility of cells.
However, one of the emerging concepts in the field is
that cellular transformation and metastatic potential are
governed by independent pathways. If true, this fact
could have major relevance in anticancer drug design
and, hopefully, in the future treatment of cancer
patients.
Ras is the small GTP-binding protein most extensively
studied as an inducer of cellular transformation. Most
recently, effort has been focused in elucidating its par-
ticipation in specific steps of the metastatic process. Ras
has been implicated in virtually all of these steps, but
the underlying mechanism is not clear. The existence of
a genetic program of ‘invasive growth’ directly activated
by Ras is one possibility, but there is no evidence
supporting this hypothesis. In fact, there are many
circumstances in which Ras itself is not able to confer a
full metastatic phenotype, and it must then work in
cooperation with other cellular alterations. Alterna-
tively, the multiple prometastatic effects of Ras may
result from its induction of genetic instability in cells, a
phenomenon strongly correlated with tumor progres-
sion. Hence, the use of Ras as a putative target for new
therapeutic agents could have a heterogeneous effect in
advanced cancers, where tumoral cells have already
accumulated several genetic lesions.
The Rho family of GTPases shares some of the charac-
teristics described for Ras, but its contribution to the
metastatic phenotype has been classically related to
effects on the cytoskeleton. However, the participation
of Rho proteins in prometastatic signaling pathways
could be more complex. They can mediate some of the
events associated with Ras-induced transformation and
at the same time play critical roles in cell adhesion
molecule pathways. Hence, overexpression or deregula-
tion of the active forms of these proteins may be partly
responsible for the aberrant cell-cell and cell-ECM rela-
tionships typical of metastatic cells. More detailed
knowledge of these pathways should lead to the identifi-
cation of targets for new pharmacological or genetic
antimetastatic agents.
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Figure 2. Role of proteins of the Ras superfamily in the activation of intracellular pathways that contribute to metastasis. Only some
selected pathways are indicated. Note that not all the described interactions between difference pathways are shown (e.g., Rac may be
activated by PI3K products, and PI3K has been shown to be activated by members of the Rho family). Members of the Rho family
mediate some of the Ras effects on cells, thus they can be placed downstream of Ras. See main text for details.
Several factors contribute to the complexity of this field.
First, the large number of members of the Ras superfam-
ily of GTPases and the cross-talk between the signal
transduction pathways in which they can participate.
Second, the inherent complexity of the metastastic pro-
cess, which requires coordination of different cellular
functions such as migration, proteolysis of ECM, prolif-
eration, and inhibition of apoptosis. Whether there is a
critical element that triggers all these cellular alterations,
and the possible involvement of the Ras GTPases in this
putative initiation event are unresolved. Finally, the
currently used models to study the metastatic phenotype
are poorly standardized, and the different backgrounds
of the cell lines employed can generate contradictory
results. Hence, much more work is needed for a clear
picture of the importance of the Ras family of GTPases
in invasion and metastasis to emerge. A combination of
reliable in vitro and especially in vivo models with clinical
data will surely contribute to this goal in the near future.
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